Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis.
Bin HuangTingting QiuChen ChenYin ZhangMichael SeidDan LovellHermine I BrunnerEsi M Morgannull nullPublished in: RMD open (2021)
Timing matters-early aggressive use with bDMARDs is more effective than conservative delayed treatment in lowering disease activity after 6 and 12 months of treatment.